Zeal Medipharma (Export) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4.74 Cr
- Revenue Growth -24.94%
- Profit Growth -2.03%
- Ebitda -6.71%
- Net Worth 47.52%
- Total Assets 31.33%
About Zeal Medipharma (Export)
Zeal Medipharma (Export) Private Limited (ZMEPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 07 May 2012 and has a history of 12 years and nine months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹4.74 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Chetan Rachchh and Shilpa Rachchh serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U51101MH2012PTC230660
- Company No.
230660
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Zeal Medipharma (Export)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shilpa Rachchh  | Director | 07-May-2012 | Current |
| Chetan Rachchh | Director | 07-May-2012 | Current |
Financial Performance of Zeal Medipharma (Export).
Zeal Medipharma (Export) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 24.94% decrease. The company also saw a slight decrease in profitability, with a 2.03% decrease in profit. The company's net worth Soared by an impressive increase of 47.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeal Medipharma (Export)?
In 2023, Zeal Medipharma (Export) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹47.37 M
Charges Breakdown by Lending Institutions
- Others : 2.79 Cr
- Standard Chartered Bank : 1.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Feb 2021 | Others | ₹2.00 Cr | Satisfied |
| 28 Dec 2016 | Others | ₹7.85 M | Satisfied |
| 06 Jan 2015 | Standard Chartered Bank | ₹1.95 Cr | Satisfied |
How Many Employees Work at Zeal Medipharma (Export)?
Unlock and access historical data on people associated with Zeal Medipharma (Export), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeal Medipharma (Export), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeal Medipharma (Export)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.